Journal of Robotic Surgery

, Volume 4, Issue 2, pp 79–86 | Cite as

Transoral robotic surgery and a paradigm shift in the management of oropharyngeal squamous cell carcinoma

  • Harry Quon
  • Bert W. O’MalleyJr
  • Gregory S. Weinstein
Review Article


Efforts to improve upon oncologic results for resectable oropharyngeal carcinoma over the past 40 years have yielded many treatment options. However, the two fundamental approaches, surgical and nonsurgical, have not been compared in a randomized trial. Both approaches can be effective and both can cause treatment-related swallowing complications. Early experience combining technological advancements with conformal radiotherapy and transoral robotic surgery suggests that the risk of swallowing complications may be reduced and that treatment outcomes may be improved through pathologic stratification and risk-adapted adjuvant therapy. This may also be a valid strategy upon which treatment de-intensification may be studied for human-papillomavirus-associated oropharyngeal carcinoma due to its favorable prognosis.


Transoral robotic surgery Oropharynx carcinoma Review Treatment paradigm Radiotherapy Concurrent chemotherapy Risk stratification Treatment-related swallowing complications 


Conflict of interest



  1. 1.
    Langendijk JA, Doornaert P, Verdonck-de Leeuw IM, Leemans CR, Aaronson NK, Slotman BJ (2008) Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. J Clin Oncol 26(22):3770–3776CrossRefPubMedGoogle Scholar
  2. 2.
    Marchetta FC (1976) Function and appearance following surgery for intraoral cancer. Clin Plast Surg 3(3):471–479PubMedGoogle Scholar
  3. 3.
    Withers EH, Franklin JD, Madden JJ Jr, Lynch JB (1979) Pectoralis major musculocutaneous flap: a new flap in head and neck reconstruction. Am J Surg 138(4):537–543CrossRefPubMedGoogle Scholar
  4. 4.
    Maccomb WS, Fletcher GH (1957) Planned combination of surgery and radiation in treatment of advanced primary head and neck cancers. Am J Roentgenol, Radium Therapy, Nucl Med 77(3):397–414Google Scholar
  5. 5.
    Jesse RH, Lindberg RD (1975) The efficacy of combining radiation therapy with a surgical procedure in patients with cervical metastasis from squamous cancer of the oropharynx and hypopharynx. Cancer 35(4):1163–1166CrossRefPubMedGoogle Scholar
  6. 6.
    Jesse RH, Fletcher GH (1977) Treatment of the neck in patients with squamous cell carcinoma of the head and neck. Cancer 39(2 Suppl):868–872CrossRefPubMedGoogle Scholar
  7. 7.
    Fletcher GH, Evers WT (1970) Radiotherapeutic management of surgical recurrences and postoperative residuals in tumors of the head and neck. Radiology 95(1):185–188PubMedGoogle Scholar
  8. 8.
    Goffinet DR, Gilbert EH, Weller SA, Bagshaw MA (1975) Irradiation of clinically uninvolved cervical lymph nodes. Can J Otolaryngol 4(5):927–933PubMedGoogle Scholar
  9. 9.
    Weller SA, Goffinet DR, Goode RL, Bagshaw MA (1976) Carcinoma of the oropharynx. Results of megavoltage radiation therapy in 305 patients. Ajr 126(2):236–247Google Scholar
  10. 10.
    Spiro RH, Gerold FP, Strong EW (1981) Mandibular “swing” approach for oral and oropharyngeal tumors. Head Neck Surg 3(5):371–378CrossRefPubMedGoogle Scholar
  11. 11.
    Kaplan R, Million RR, Cassisi NJ (1977) Carcinoma of the tonsil: results of radical irradiation with surgery reserved for radiation failure. Laryngoscope 87(4Pt1):600–607PubMedGoogle Scholar
  12. 12.
    Strong MS, Vaughan CW, Kayne HL, Aral IM, Ucmakli A, Feldman M et al (1978) A randomized trial of preoperative radiotherapy in cancer of the oropharynx and hypopharynx. Am J Surg 136(4):494–500CrossRefPubMedGoogle Scholar
  13. 13.
    Quenelle DJ, Crissman JD, Shumrick DA (1979) Tonsil carcinoma–treatment results. Laryngoscope 89(11):1842–1846CrossRefPubMedGoogle Scholar
  14. 14.
    Gullane PJ, Jabbour JM, Conley JJ, Nealon TF Jr (1979) Correlation of pharyngeal fistulization with preoperative radiotherapy, reduced serum albumen, and dietary obstruction. Otolaryngol Head Neck Surg 87(3):311–317PubMedGoogle Scholar
  15. 15.
    Tupchong L, Scott CB, Blitzer PH, Marcial VA, Lowry LD, Jacobs JR, et al. (1991) Randomized study of preoperative versus postoperative radiation therapy in advanced head and neck carcinoma: long-term follow-up of RTOG study 73-03. Int J Radiat Oncol Biol Phys 20(1):21–28Google Scholar
  16. 16.
    The Department of Veterans Affairs Laryngeal Cancer Study Group (1991) Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 324(24):1685–1690Google Scholar
  17. 17.
    Withers HR (1985) Biologic basis for altered fractionation schemes. Cancer 55(9 Suppl):2086–2095CrossRefPubMedGoogle Scholar
  18. 18.
    Fu KK, Pajak TF, Trotti A, Jones CU, Spencer SA, Phillips TL et al. (2000) A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 48(1):7–16Google Scholar
  19. 19.
    Bourhis J, Overgaard J, Audry H, Ang KK, Saunders M, Bernier J et al (2006) Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 368(9538):843–854CrossRefPubMedGoogle Scholar
  20. 20.
    Adelstein DJ, Saxton JP, Rybicki LA, Esclamado RM, Wood BG, Strome M et al (2006) Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution. J Clin Oncol 24(7):1064–1071CrossRefPubMedGoogle Scholar
  21. 21.
    Calais G, Alfonsi M, Bardet E, Sire C, Germain T, Bergerot P et al. (2000) Stage III and IV cancers of the oropharynx: results of a randomized study of Gortec comparing radiotherapy alone with concomitant chemotherapy. Bulletin du Cancer 87 Spec No:48–53Google Scholar
  22. 22.
    Brizel DM, Albers ME, Fisher SR, Scher RL, Richtsmeier WJ, Hars V et al (1998) Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 338(25):1798–1804CrossRefPubMedGoogle Scholar
  23. 23.
    Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, Greiner RH et al (2004) Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350(19):1945–1952CrossRefPubMedGoogle Scholar
  24. 24.
    Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB et al (2004) Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350(19):1937–1944CrossRefPubMedGoogle Scholar
  25. 25.
    Pignon JP, le Maitre A, Maillard E, Bourhis J (2009) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17, 346 patients. Radiother Oncol 92(1):4–14CrossRefPubMedGoogle Scholar
  26. 26.
    Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V et al (2007) Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357(17):1705–1715CrossRefPubMedGoogle Scholar
  27. 27.
    Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M et al (2007) Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357(17):1695–1704CrossRefPubMedGoogle Scholar
  28. 28.
    Hitt R, Grau JJ, Lopez-Pousa A, Berrocal A, Garcia Giron C, Irigoyen A et al. (2009) Final results of a randomized phase III trial comparing induction chemotherapy with cisplatin/5-FU or docetaxel/cisplatin/5-FU follow by chemoradiotherapy (CRT) versus CRT alone as first-line treatment of unresectable locally advanced head and neck cancer (LAHNC). ASCO Meeting Abstracts. 5/20;27(15S):6009Google Scholar
  29. 29.
    Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354(6):567–578CrossRefPubMedGoogle Scholar
  30. 30.
    Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK et al (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11(1):21–28CrossRefPubMedGoogle Scholar
  31. 31.
    Rischin D, Hicks RJ, Fisher R, Binns D, Corry J, Porceddu S et al. (2006) Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol 24(13):2098–2104Google Scholar
  32. 32.
    Overgaard J, Horsman MR (1996) Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol 6(1):10–21CrossRefPubMedGoogle Scholar
  33. 33.
    Le QT, Taira A, Budenz S, Jo Dorie M, Goffinet DR, Fee WE et al (2006) Mature results from a randomized Phase II trial of cisplatin plus 5-fluorouracil and radiotherapy with or without tirapazamine in patients with resectable Stage IV head and neck squamous cell carcinomas. Cancer 106(9):1940–1949CrossRefPubMedGoogle Scholar
  34. 34.
    Rischin D, Peters L, Fisher R, Macann A, Denham J, Poulsen M et al. (2005) Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-tasman radiation oncology group (TROG 98.02). J Clin Oncol 23(1):79–87Google Scholar
  35. 35.
    Caudell JJ, Schaner PE, Meredith RF, Locher JL, Nabell LM, Carroll WR et al. (2009) Factors associated with long-term dysphagia after definitive radiotherapy for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 73(2):410–415Google Scholar
  36. 36.
    Langendijk JA, Doornaert P, Rietveld DH, Verdonck-de Leeuw IM, Leemans CR, Slotman BJ (2009) A predictive model for swallowing dysfunction after curative radiotherapy in head and neck cancer. Radiother Oncol 90(2):189–195CrossRefPubMedGoogle Scholar
  37. 37.
    Machtay M, Moughan J, Trotti A, Garden AS, Weber RS, Cooper JS et al (2008) Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 26(21):3582–3589CrossRefPubMedGoogle Scholar
  38. 38.
    Feng FY, Kim HM, Lyden TH, Haxer MJ, Feng M, Worden FP et al. (2007) Intensity-modulated radiotherapy of head and neck cancer aiming to reduce dysphagia: early dose-effect relationships for the swallowing structures. Int J Radiat Oncol Biol Phys 68(5):1289–1298Google Scholar
  39. 39.
  40. 40.
    Levendag PC, Teguh DN, Voet P, van der Est H, Noever I, de Kruijf WJ et al (2007) Dysphagia disorders in patients with cancer of the oropharynx are significantly affected by the radiation therapy dose to the superior and middle constrictor muscle: a dose-effect relationship. Radiother Oncol 85(1):64–73CrossRefPubMedGoogle Scholar
  41. 41.
    Gillison ML, Harris J, Westra W, Chung C, Jordan R, Rosenthal D et al. (2009) Survival outcomes by tumor human papillomavirus (HPV) status in stage III-IV oropharyngeal cancer (OPC) in RTOG 0129. J Clin Oncol (Meeting Abstracts). 27(15S):6003Google Scholar
  42. 42.
    Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H et al (2008) Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 100(4):261–269CrossRefPubMedGoogle Scholar
  43. 43.
    Licitra L, Perrone F, Bossi P, Suardi S, Mariani L, Artusi R et al (2006) High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 24(36):5630–5636CrossRefPubMedGoogle Scholar
  44. 44.
    Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L et al (2000) Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92(9):709–720CrossRefPubMedGoogle Scholar
  45. 45.
    Dosoretz A, Dutta PR, Lin A, Alonso-Basanta M, BarAd V, Both S et al. (2010) Long-term percutaneous gastrostomy tube dependence rates in patients treated with intensity-modulated radiotherapy for oropharyngeal cancer: the university of pennsylvania experience. AHNS/ASCO/ASTRO Multi-Disciplinary Head and Neck Cancer Symposium; Chandler, Arizona, poster 14, p 49Google Scholar
  46. 46.
    Moore EJ, Olsen KD, Kasperbauer JL (2009) Transoral robotic surgery for oropharyngeal squamous cell carcinoma: a prospective study of feasibility and functional outcomes. Laryngoscope 119(11):2156–2164CrossRefPubMedGoogle Scholar
  47. 47.
    Grant DG, Hinni ML, Salassa JR, Perry WC, Hayden RE, Casler JD (2009) Oropharyngeal cancer: a case for single modality treatment with transoral laser microsurgery. Arch Otolaryngol Head Neck Surg 135(12):1225–1230Google Scholar
  48. 48.
    Steiner W, Fierek O, Ambrosch P, Hommerich CP, Kron M (2003) Transoral laser microsurgery for squamous cell carcinoma of the base of the tongue. Arch Otolaryngol Head Neck Surg 129(1):36–43Google Scholar
  49. 49.
    Rich JT, Milov S, Lewis JS Jr, Thorstad WL, Adkins DR, Haughey BH (2009) Transoral laser microsurgery (TLM) ± adjuvant therapy for advanced stage oropharyngeal cancer: outcomes and prognostic factors. Laryngoscope 119(9):1709–1719CrossRefPubMedGoogle Scholar
  50. 50.
    Laccourreye O, Hans S, Menard M, Garcia D, Brasnu D, Holsinger FC (2005) Transoral lateral oropharyngectomy for squamous cell carcinoma of the tonsillar region: II. An analysis of the incidence, related variables, and consequences of local recurrence. Arch Otolaryngol Head Neck Surg 131(7):592–599Google Scholar
  51. 51.
    Worden FP, Hooton J, Lee J, Eisbruch A, Wolf GT, Prince M et al. (2009) Association of tobacco (T) use with risk of distant metastases (DM), tumor recurrence, and death in patients (pts) with HPV-positive (+) squamous cell cancer of the oropharynx (SCCOP). J Clin Oncol (Meeting Abstracts). 27(15S):6001Google Scholar
  52. 52.
    Fischer CA, Zlobec I, Green E, Probst S, Storck C, Lugli A et al (2009) Is the improved prognosis of p16 positive oropharyngeal squamous cell carcinoma dependent of the treatment modality? Int J Cancer 126(5):1256–1262Google Scholar
  53. 53.
    Weinberger PM, Yu Z, Haffty BG, Kowalski D, Harigopal M, Brandsma J et al (2006) Molecular classification identifies a subset of human papillomavirus–associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 24(5):736–747CrossRefPubMedGoogle Scholar
  54. 54.
    Lassen P, Eriksen JG, Hamilton-Dutoit S, Tramm T, Alsner J, Overgaard J (2010) HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer. Radiother Oncol 94(1):30–35Google Scholar

Copyright information

© Springer-Verlag London Ltd 2010

Authors and Affiliations

  • Harry Quon
    • 1
    • 2
    • 3
    • 4
    • 5
  • Bert W. O’MalleyJr
    • 2
    • 3
    • 4
  • Gregory S. Weinstein
    • 2
    • 3
    • 4
  1. 1.Department of Radiation OncologyPhiladelphiaUSA
  2. 2.Department of Otorhinolaryngology–Head and Neck SurgeryPhiladelphiaUSA
  3. 3.Abramson Cancer CenterPhiladelphiaUSA
  4. 4.University of PennsylvaniaPhiladelphiaUSA
  5. 5.Hospital of the University of PennsylvaniaPhiladelphiaUSA

Personalised recommendations